

# Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against

New England Journal of Medicine

384, 1885-1898

DOI: [10.1056/nejmoa2102214](https://doi.org/10.1056/nejmoa2102214)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Challenges of COVID-19 vaccination in the context of transplantation - A narrative review. Indian Journal of Transplantation, 2021, 15, 134.	0.0	0
2	Clinical Characteristics of COVID-19 by SARS-CoV-2 Gamma Variant in Vaccinated and Non-Vaccinated Healthcare Workers. SSRN Electronic Journal, 0, , .	0.4	0
3	Quantifying Healthcare Worker's Preferences Around COVID-19 Vaccination: A Single-Profile DCE Study in France. SSRN Electronic Journal, 0, , .	0.4	0
4	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multi-epitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging Microbes and Infections, 2021, 10, 1931-1946.	3.0	11
5	An overview of current COVID-19 vaccine platforms. Computational and Structural Biotechnology Journal, 2021, 19, 2508-2517.	1.9	99
6	OUP accepted manuscript. American Journal of Clinical Pathology, 2021, , .	0.4	7
7	Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America. SSRN Electronic Journal, 0, , .	0.4	7
8	The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants. Journal of Infectious Diseases, 2022, 225, 934-937.	1.9	3
9	Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerging Microbes and Infections, 2021, 10, 1751-1759.	3.0	206
10	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerging Microbes and Infections, 2021, 10, 1284-1292.	3.0	25
11	Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2. Informatics in Medicine Unlocked, 2021, 24, 100569.	1.9	14
12	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
16	Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature, 2021, 593, 142-146.	18.7	574
17	Delaying the second dose of covid-19 vaccines. BMJ, The, 2021, 372, n710.	3.0	20
19	Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?. British Journal of Clinical Pharmacology, 2021, 87, 2405-2406.	1.1	4
20	Rare COVID reactions might hold key to variant-proof vaccines. Nature, 2021, 592, 20-21.	18.7	8
23	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021, 7, 512-533.	5.3	217
24	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Frontiers in Immunology, 2021, 12, 589095.	2.2	102

#	ARTICLE	IF	CITATIONS
25	Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. <i>Lancet, The</i> , 2021, 397, 1263-1264.	6.3	49
29	Will SARS-CoV-2 variants of concern affect the promise of vaccines?. <i>Nature Reviews Immunology</i> , 2021, 21, 340-341.	10.6	162
30	Pandemic moves and countermoves: vaccines and viral variants. <i>Lancet, The</i> , 2021, 397, 1326-1327.	6.3	29
31	An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. <i>Vaccines</i> , 2021, 9, 433.	2.1	85
32	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
35	COVID-19: which lessons have we learned?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1009-1011.	1.4	2
36	Africa needs more genome sequencing to tackle new variants of SARS-CoV-2. <i>Nature Medicine</i> , 2021, 27, 744-745.	15.2	18
38	Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	216
40	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 669339.	2.2	81
42	Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. <i>Nature Medicine</i> , 2021, 27, 993-998.	15.2	161
43	SARS-CoV-2 vaccines: a triumph of science and collaboration. <i>JCI Insight</i> , 2021, 6, .	2.3	72
45	SARS-CoV-2 spike therapeutic antibodies in the age of variants. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	11
50	Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA. <i>Molecular Frontiers Journal</i> , 2021, 05, 38-57.	0.9	6
52	The importance of genomic analysis in cracking the coronavirus pandemic. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 547-562.	1.5	14
53	Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation. <i>Life</i> , 2021, 11, 375.	1.1	9
59	BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity. <i>Clinical Infectious Diseases</i> , 2022, 74, 517-520.	2.9	36
61	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1899-1909.	13.9	541
65	SARS-CoV-2 vaccines: anamnestic response in previously infected recipients. <i>Cell Research</i> , 2021, 31, 827-828.	5.7	15

#	ARTICLE	IF	CITATIONS
71	The need for global access to biomedical innovations during pandemics. <i>Nature Biotechnology</i> , 2021, 39, 664-666.	9.4	13
73	COVID-19 vaccines: progress and understanding on quality control and evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 199.	7.1	21
74	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 35-45.	3.8	634
75	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
76	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 665-706.	0.4	12
78	RSV genomic diversity and the development of a globally effective RSV intervention. <i>Vaccine</i> , 2021, 39, 2811-2820.	1.7	5
80	COVID-19: vaccine™s progress. <i>Microbial Biotechnology</i> , 2021, 14, 1246-1257.	2.0	16
81	Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control. <i>New England Journal of Medicine</i> , 2021, 384, 1952-1954.	13.9	19
82	COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant. <i>BMJ Global Health</i> , 2021, 6, e006012.	2.0	28
83	Development of leading first-generation vaccines against SARS-CoV-2. <i>Microbes and Infection</i> , 2021, 23, 104841.	1.0	0
84	The Emerging Concern and Interest SARS-CoV-2 Variants. <i>Pathogens</i> , 2021, 10, 633.	1.2	86
86	Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. <i>Journal of Medical Virology</i> , 2021, 93, 5638-5643.	2.5	129
87	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. <i>Nature Medicine</i> , 2021, 27, 759-761.	15.2	65
89	Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient. <i>Clinical Infectious Diseases</i> , 2021, 73, 2144-2145.	2.9	32
94	Insights into SARS-CoV-2 Persistence and Its Relevance. <i>Viruses</i> , 2021, 13, 1025.	1.5	37
95	Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	16
96	Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages. <i>Lancet Public Health</i> , The, 2021, 6, e267-e268.	4.7	30
99	Forecasting COVID-19 cases: A comparative analysis between recurrent and convolutional neural networks. <i>Results in Physics</i> , 2021, 24, 104137.	2.0	43

#	ARTICLE	IF	CITATIONS
101	A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. <i>MedComm</i> , 2021, 2, 430-441.	3.1	37
103	The Emergence of SARS-CoV-2 Variant(s) and Its Impact on the Prevalence of COVID-19 Cases in the Nabatieh Region, Lebanon. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 40.	1.3	14
107	Observational study on healthcare workers protection in the angiographic suite during the SARS-CoV-2 pandemic: before and during vax era. <i>Journal of Public Health Research</i> , 2021, 10, .	0.5	1
108	Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. <i>Reviews in Medical Virology</i> , 2022, 32, e2270.	3.9	71
109	Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	16
110	New variants of SARS-CoV-2. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 419-428.	0.5	49
112	Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. <i>Lancet, The</i> , 2021, 397, 2331-2333.	6.3	490
113	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
115	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	13.7	549
116	In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. <i>Frontiers in Microbiology</i> , 2021, 12, 698944.	1.5	40
119	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. <i>American Journal of Hematology</i> , 2021, 96, 896-900.	2.0	12
121	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
123	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007.	1.8	21
124	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3546-3567.	2.0	152
125	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650
127	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. <i>Scientific Reports</i> , 2021, 11, 12740.	1.6	54
129	Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 118-123.	0.6	18
130	Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead. <i>Bioengineering</i> , 2021, 8, 84.	1.6	12

#	ARTICLE	IF	CITATIONS
131	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15
132	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
135	Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide. <i>Osong Public Health and Research Perspectives</i> , 2021, 12, 139-148.	0.7	9
137	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	1.0	15
140	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. <i>Vaccines</i> , 2021, 9, 702.	2.1	5
142	CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4048.	5.8	45
143	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211.	1.5	35
144	Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease. <i>Frontiers in Medicine</i> , 2021, 8, 637642.	1.2	7
146	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S6-S18.	0.8	16
148	Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	656
149	Hybrid immunity. <i>Science</i> , 2021, 372, 1392-1393.	6.0	218
151	Six months of COVID vaccines: what 1.7 billion doses have taught scientists. <i>Nature</i> , 2021, 594, 164-167.	13.7	61
153	Impact of spike genetic variants in vaccines against SARS-CoV-2. <i>Vacunas (English Edition)</i> , 2021, 22, 59-61.	0.3	0
156	Rapid Inactivation of SARS-CoV-2 Variants by Continuous and Intermittent Irradiation with a Deep-Ultraviolet Light-Emitting Diode (DUV-LED) Device. <i>Pathogens</i> , 2021, 10, 754.	1.2	17
157	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , 2021, 35, 109292.	2.9	375
158	COVID-19 and Preparing for Future Ecological Crises: Hopes from Metagenomics in Facing Current and Future Viral Pandemic Challenges. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 336-341.	1.0	2
159	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8
160	Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3491-3494.	1.4	37

#	ARTICLE	IF	CITATIONS
161	COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. <i>Frontiers in Genetics</i> , 2021, 12, 693916.	1.1	55
164	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
165	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. <i>Journal of Virology</i> , 2021, 95, e0020321.	1.5	35
167	A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 278.	7.1	6
168	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1784-1789.	2.8	54
169	How to interpret and use COVID-19 serology and immunology tests. <i>Clinical Microbiology and Infection</i> , 2021, 27, 981-986.	2.8	94
170	The variants question: What is the problem?. <i>Journal of Medical Virology</i> , 2021, 93, 6479-6485.	2.5	26
171	COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. <i>Journal of Intensive Medicine</i> , 2021, 1, 4-13.	0.8	9
172	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. <i>Frontiers in Immunology</i> , 2021, 12, 701501.	2.2	157
173	Early detection of P.1 variant of SARS-CoV-2 in a cluster of cases in Salvador, Brazil. <i>International Journal of Infectious Diseases</i> , 2021, 108, 252-255.	1.5	17
174	Specific allelic discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B.1.1.7 lineage in Washington State. <i>Journal of Medical Virology</i> , 2021, 93, 5931-5941.	2.5	31
175	ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 385, 571-572.	13.9	42
176	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. <i>BMC Medicine</i> , 2021, 19, 173.	2.3	156
178	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
179	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021, 36, 109452.	2.9	90
180	Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10
181	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. <i>Current Medical Science</i> , 2021, 41, 1037-1051.	0.7	136
182	A "mix and match" approach to SARS-CoV-2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1510-1511.	15.2	45

#	ARTICLE	IF	CITATIONS
183	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC): Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.1	94
185	These archaeologists helped quell a COVID surge in Madagascar. <i>Nature</i> , 2021, , .	13.7	1
186	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 781.	2.1	28
188	Immunoinformatics approach for multi-epitope vaccine design against structural proteins and ORF1a polyprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2021, 7, 22.	0.9	17
189	COVID-19 Vaccines and Thrombosisâ€”Roadblock or Dead-End Street?. <i>Biomolecules</i> , 2021, 11, 1020.	1.8	28
190	Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0085921.	1.8	82
192	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
193	In Silico Design of Peptide-Based SARS-CoV-2 Fusion Inhibitors That Target WT and Mutant Versions of SARS-CoV-2 HR1 Domains. <i>Biophysica</i> , 2021, 1, 311-327.	0.6	8
195	Navigating post-vaccine COVID-19 futures in the health and economic context. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 893-894.	4.6	3
196	Hypothesis: Possible influence of antivector immunity and SARSâ€CoVâ€2 variants on efficacy of ChAdOx1 nCoVâ€19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	2.7	11
197	Efficacy of COVID-19 vaccines: From clinical trials to real life. <i>Therapie</i> , 2021, 76, 277-283.	0.6	30
199	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
201	Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. <i>Virology Journal</i> , 2021, 18, 154.	1.4	29
203	COVID-19 transmission and the safety of air travel during the pandemic: a scoping review. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 415-422.	1.3	13
204	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
205	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. <i>Biomedicines</i> , 2021, 9, 903.	1.4	5
206	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. <i>Clinical Infectious Diseases</i> , 2022, 74, 734-742.	2.9	88
207	The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. <i>Cell</i> , 2021, 184, 3949-3961.e11.	13.5	171



#	ARTICLE	IF	CITATIONS
208	Potential COVID-19 Endgame Scenarios. JAMA - Journal of the American Medical Association, 2021, 326, 303.	3.8	26
209	After the pandemic: perspectives on the future trajectory of COVID-19. Nature, 2021, 596, 495-504.	13.7	260
212	Broad sarbecovirus neutralization by a human monoclonal antibody. Nature, 2021, 597, 103-108.	13.7	220
213	Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Critical Care, 2021, 25, 244.	2.5	186
214	The Genomic Landscape of Severe Acute Respiratory Syndrome Coronavirus 2. Advances in Molecular Pathology, 2021, 4, 231-235.	0.2	4
216	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nature Communications, 2021, 12, 4598.	5.8	88
217	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain and Therapy, 2021, 10, 1309-1330.	1.5	28
219	Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. Wellcome Open Research, 0, 6, 185.	0.9	17
220	Coding-Complete Genome Sequences of 11 SARS-CoV-2 B.1.1.7 and B.1.351 Variants from Metro Manila, Philippines. Microbiology Resource Announcements, 2021, 10, e0049821.	0.3	5
221	Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine, 2021, 39, 4423-4428.	1.7	766
222	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Npj Vaccines, 2021, 6, 104.	2.9	241
223	Rapid evolution of the COVID-19 pandemic calls for a unified public health response. BioScience Trends, 2021, 15, 196-200.	1.1	5
225	SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. Microorganisms, 2021, 9, 1744.	1.6	16
226	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	2.1	50
227	Immunity to SARS-CoV-2 induced by infection or vaccination. Journal of Internal Medicine, 2022, 291, 32-50.	2.7	97
228	Drug Repurposing Against SARS-CoV-2: Targeting NSP16-NSP10 Interaction. Journal of the Turkish Chemical Society, Section A: Chemistry, 0, , 933-940.	0.4	1
229	SARS-CoV-2 Vaccines: Where Are We Now?. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3535-3543.	2.0	36
230	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine, 2021, 38, 101010.	3.2	28

#	ARTICLE	IF	CITATIONS
231	Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. <i>Cell</i> , 2021, 184, 4401-4413.e10.	13.5	65
232	Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8663.	1.8	18
233	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
234	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. <i>Vaccines</i> , 2021, 9, 869.	2.1	17
236	COVID-19 vaccination in patients with $\alpha$ 1-antitrypsin deficiency. <i>Lancet Respiratory Medicine</i> , 2021, 9, 818-820.	5.2	2
237	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
238	SARS-CoV-2 vaccines â€” the biggest medical research project of the 21st century. <i>Current Opinion in Virology</i> , 2021, 49, 52-57.	2.6	12
239	Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination â€” A riskâ€”benefit analysis for people $\geq 60$ years in Australia. <i>Vaccine</i> , 2021, 39, 4784-4787.	1.7	25
241	Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAcatch Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2765-2776.	1.8	65
242	Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager. <i>Vaccine</i> , 2021, 39, 4921-4924.	1.7	10
243	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus diseaseâ€”19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
244	2020 Hindsight: Should evolutionary virologists have expected the unexpected during a pandemic?. <i>Evolution; International Journal of Organic Evolution</i> , 2021, 75, 2311-2316.	1.1	6
245	Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York. <i>Nature</i> , 2021, 597, 703-708.	13.7	103
246	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	10.6	777
247	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
248	Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2. <i>Frontiers in Medicine</i> , 2021, 8, 721286.	1.2	11
249	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. <i>Pathogens</i> , 2021, 10, 1030.	1.2	33
251	An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. <i>Frontiers in Pharmacology</i> , 2021, 12, 717757.	1.6	28

#	ARTICLE	IF	CITATIONS
253	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
254	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
255	Early warning and rapid public health response to prevent COVID-19 outbreaks in long-term care facilities (LTCF) by monitoring SARS-CoV-2 RNA in LTCF site-specific sewage samples and assessment of antibodies response in this population: prospective study protocol. <i>BMJ Open</i> , 2021, 11, e052282.	0.8	6
256	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
257	Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3459-3476.	1.1	179
258	The effect of negationism on public health. <i>Journal of Human Growth and Development</i> , 2021, 31, 189-191.	0.2	3
259	The rapid adaptation of SARS-CoV-2â€™rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
260	The characteristics of SARSâ€™CoVâ€™2â€™positive children who presented to Australian hospitals during 2020: a PREDICT network study. <i>Medical Journal of Australia</i> , 2021, 215, 217-221.	0.8	12
261	Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19. <i>Pharmaceutics</i> , 2021, 13, 1260.	2.0	11
262	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
263	COVID-19 Research: Lessons from Non-Human Primate Models. <i>Vaccines</i> , 2021, 9, 886.	2.1	15
264	Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. <i>Epidemiology</i> , 2021, 32, 820-828.	1.2	9
265	Opinion on the Policy of Lifting Restrictions to Entry Under the Circumstance of the COVID-19 Pandemic. <i>Infectious Diseases &amp; Immunity</i> , 2021, Publish Ahead of Print, .	0.2	0
267	Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains. <i>Vaccines</i> , 2021, 9, 920.	2.1	16
268	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
272	In-depth profiling of COVID-19 risk factors and preventive measures in healthcare workers. <i>Infection</i> , 2022, 50, 381-394.	2.3	17
275	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. <i>Vaccines</i> , 2021, 9, 914.	2.1	20
277	Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. <i>Postgraduate Medical Journal</i> , 2022, 98, 389-394.	0.9	137

#	ARTICLE	IF	CITATIONS
280	Novel SARS-CoV-2 variants: the pandemics within the pandemic. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1109-1117.	2.8	290
281	Understanding the devastating second wave of COVID-19 pandemic in India. <i>American Journal of Human Biology</i> , 2021, 33, e23671.	0.8	4
282	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	5.8	22
283	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicine</i> , 2021, 9, 1163.	1.4	18
284	Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic surveillance. <i>Journal of Medical Virology</i> , 2022, 94, 32-34.	2.5	7
286	Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants. <i>PLoS Computational Biology</i> , 2021, 17, e1009380.	1.5	13
290	Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. <i>Dermatology and Therapy</i> , 2021, 11, 1889-1903.	1.4	6
291	Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective. <i>Life Sciences</i> , 2021, 280, 119744.	2.0	11
292	Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 1049-1051.	13.9	137
293	Bispecific antibodies targeting distinct regions of the spike protein potentially neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79
294	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013825.	1.5	114
295	Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA. <i>Molecular Biomedicine</i> , 2021, 2, 29.	1.7	10
296	Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 258-270.	2.7	27
297	SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4687-4700.	2.5	26
298	Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. <i>iScience</i> , 2021, 24, 103037.	1.9	66
299	The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 561-563.	0.6	4
300	An ultrapotent pan- $\beta$ -coronavirus lineage B ( $\beta$ -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
302	Beta testing the monkey model. <i>Nature Immunology</i> , 2021, 22, 1201-1203.	7.0	0

#	ARTICLE	IF	CITATIONS
303	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021, 9, 1097.	2.1	27
304	COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. <i>Cell</i> , 2021, 184, 5077-5081.	13.5	114
305	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	2.1	124
306	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	1.5	10
307	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	4.7	83
309	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 2348-2360.	13.9	458
310	Vaccines for COVID-19: Where do we stand in 2021?. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 22-31.	1.2	53
312	The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants. <i>Current Medicinal Chemistry</i> , 2022, 29, 2673-2690.	1.2	12
314	The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 340.	7.1	48
315	Interactions of the Receptor Binding Domain of SARS-CoV-2 Variants with hACE2: Insights from Molecular Docking Analysis and Molecular Dynamic Simulation. <i>Biology</i> , 2021, 10, 880.	1.3	38
316	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
318	Priorities for global access to life-saving interventions during public health emergencies: Crisis nationalism, solidarity or charity?. <i>Global Public Health</i> , 2021, , 1-10.	1.0	6
319	Review of COVID-19 viral vector-based vaccines and COVID-19 variants. <i>Infezioni in Medicina</i> , 2021, 29, 328-338.	0.7	35
320	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
321	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
323	Positivity rate: an indicator for the spread of COVID-19. <i>Current Medical Research and Opinion</i> , 2021, 37, 2067-2076.	0.9	13
324	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
325	Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants. <i>Journal of Biological Chemistry</i> , 2021, 297, 101208.	1.6	37

#	ARTICLE	IF	CITATIONS
327	Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. <i>Nature Communications</i> , 2021, 12, 5730.	5.8	90
329	WHotLAMP: A simple, inexpensive, and sensitive molecular test for the detection of SARS-CoV-2 in saliva. <i>PLoS ONE</i> , 2021, 16, e0257464.	1.1	2
330	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>in Vitro</i> and <i>in Vivo</i> . <i>Journal of Virology</i> , 2021, 95, e0112621.	1.5	13
331	Implementing vaccination policies based upon scientific evidence in Japan. <i>Vaccine</i> , 2021, 39, 5447-5450.	1.7	2
332	Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK. <i>Lancet Microbe</i> , The, 2021, 2, e416-e418.	3.4	16
334	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
335	COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF- $\kappa$ B Pathway. <i>Viruses</i> , 2021, 13, 1887.	1.5	12
338	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100171.	3.0	70
339	SARS-CoV-2-specific T cells in infection and vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2307-2312.	4.8	131
340	Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 32-39.	1.2	18
341	Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Pathology Research and Practice</i> , 2021, 225, 153565.	1.0	8
342	The Potential Beneficial Effects of Vaccination on Antigenically Evolving Pathogens. <i>American Naturalist</i> , 2022, 199, 223-237.	1.0	6
343	Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. <i>EClinicalMedicine</i> , 2021, 39, 101064.	3.2	116
344	Biological and Clinical Factors Contributing to the Metabolic Heterogeneity of Hospitalized Patients with and without COVID-19. <i>Cells</i> , 2021, 10, 2293.	1.8	37
345	Association of E484K spike protein mutation with SARS-CoV-2 infection in vaccinated persons—Maryland, January 2021–May 2021. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	10
346	Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 2025-2031.	15.2	361
349	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 740-750.	3.6	83
350	Coming to terms with COVID-19 personally and professionally in Bangladesh. <i>The Lancet Global Health</i> , 2021, 9, e1471-e1473.	2.9	3

#	ARTICLE	IF	CITATIONS
351	COVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 15, 100256.	1.3	15
352	Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1351-1352.	4.6	18
353	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003769.	3.9	83
354	Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors. <i>The Lancet Global Health</i> , 2021, 9, e1363-e1364.	2.9	9
355	AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?. <i>Journal of Neuroimmunology</i> , 2021, 360, 577719.	1.1	36
356	Immune response variables and viral mutations impact on COVID-19 reinfection and relapse. <i>International Immunopharmacology</i> , 2021, 100, 108108.	1.7	7
357	COVID-19 variants in India: Potential role in second wave and impact on vaccination. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 784-787.	0.8	24
358	Accessible detection of SARS-CoV-2 through molecular nanostructures and automated microfluidics. <i>Biosensors and Bioelectronics</i> , 2021, 194, 113629.	5.3	21
359	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	1.2	18
361	Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey. <i>International Journal of Epidemiology</i> , 2022, 51, 404-417.	0.9	29
363	Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic. <i>Pharmacology</i> , 2021, 106, 462-468.	0.9	16
366	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. <i>Science</i> , 2021, 374, 423-431.	6.0	144
369	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
370	Coronavirus Disease 2019 Vaccines and Pregnancy: Present and Future. <i>Perinatology</i> , 2021, 32, 111.	0.0	0
371	Role of artificial intelligence in peptide vaccine design against RNA viruses. <i>Informatics in Medicine Unlocked</i> , 2021, 26, 100768.	1.9	10
372	Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
373	COVID-19 Vaccines: Adenoviral Vectors. <i>Annual Review of Medicine</i> , 2022, 73, 41-54.	5.0	46
374	Effectiveness of COVID-19 vaccines and their challenges (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1407.	0.8	23



#	ARTICLE	IF	CITATIONS
375	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	2.9	36
376	HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. <i>ELife</i> , 2021, 10, .	2.8	28
377	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2009.	1.5	9
378	Cellular senescence as a source of SARS-CoV-2 quasispecies. <i>FEBS Journal</i> , 2023, 290, 1384-1392.	2.2	12
379	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	1.3	7
380	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
381	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9
382	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2673-2675.	4.8	25
383	mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. <i>ELife</i> , 2021, 10, .	2.8	63
384	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
385	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. <i>Science Advances</i> , 2021, 7, eabj3627.	4.7	24
387	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
388	Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients. <i>Transplantation Proceedings</i> , 2022, 54, 1399-1404.	0.3	16
389	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
390	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
391	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
392	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
393	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90



#	ARTICLE	IF	CITATIONS
394	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	3.3	17
395	They have produced a vaccine, but we doubt if COVID-19 exists : correlates of COVID-19 vaccine acceptability among adults in Kano, Nigeria. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4057-4064.	1.4	30
396	Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 –May 2021. <i>PLoS ONE</i> , 2021, 16, e0258513.	1.1	37
397	The COVID-19 pandemic: viral variants and vaccine efficacy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 66-75.	2.7	61
398	Lethal Interactions of SARS-CoV-2 with Graphene Oxide: Implications for COVID-19 Treatment. <i>ACS Applied Nano Materials</i> , 2021, 4, 11881-11887.	2.4	33
400	Rapid Proliferation of Pandemic Research: Implications for Dual-Use Risks. <i>MBio</i> , 2021, 12, e0186421.	1.8	9
401	SARS-CoV-2 Virus~Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10836.	1.8	25
402	Facile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA. <i>Nanomaterials</i> , 2021, 11, 2816.	1.9	11
403	Quantifying healthcare and welfare sector workers™ preferences around COVID-19 vaccination: a cross-sectional, single-profile discrete-choice experiment in France. <i>BMJ Open</i> , 2021, 11, e055148.	0.8	6
404	Structural Insights on the SARS-CoV-2 Variants of Concern Spike Glycoprotein: A Computational Study With Possible Clinical Implications. <i>Frontiers in Genetics</i> , 2021, 12, 773726.	1.1	3
406	A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. <i>Vaccine</i> , 2021, 39, 6585-6590.	1.7	26
408	Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020. <i>Nature Communications</i> , 2021, 12, 6009.	5.8	17
410	Benefits of COVID-19 non-pharmaceutical interventions on the prevention of other notifiable infectious diseases. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 17, 100303.	1.3	3
411	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
412	Data-driven analysis of amino acid change dynamics timely reveals SARS-CoV-2 variant emergence. <i>Scientific Reports</i> , 2021, 11, 21068.	1.6	15
413	Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo. <i>Nature Communications</i> , 2021, 12, 6220.	5.8	62
414	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	1.1	5
415	Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. <i>Nature Communications</i> , 2021, 12, 6238.	5.8	31

#	ARTICLE	IF	CITATIONS
417	Cognitive Barriers to COVID-19 Vaccine Uptake Among Older Adults. <i>Frontiers in Medicine</i> , 2021, 8, 756275.	1.2	11
418	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. <i>Cells</i> , 2021, 10, 2949.	1.8	26
419	Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. <i>Immunity</i> , 2021, 54, 2908-2921.e6.	6.6	35
420	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
421	Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain. <i>Frontiers in Global Women S Health</i> , 2021, 2, 761511.	1.1	52
423	Multicomponent vaccines to fight SARS-CoV-2 variants of concern. <i>Vaccine</i> , 2021, 39, 6969-6971.	1.7	4
425	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). <i>Clinics in Laboratory Medicine</i> , 2022, 42, 111-128.	0.7	8
426	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
427	The impact of public health interventions in the Nordic countries during the first year of SARS-CoV-2 transmission and evolution. <i>Eurosurveillance</i> , 2021, 26, .	3.9	8
428	Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1899-1905.	2.9	15
429	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
430	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
433	Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. <i>Infectious Diseases &amp; Immunity</i> , 2022, 2, 29-33.	0.2	3
434	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. <i>Translational Research</i> , 2022, 240, 1-16.	2.2	33
435	Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 759108.	1.3	25
436	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
437	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
439	ACE2 and S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2021, 2021, 1-10.	0.7	5

#	ARTICLE	IF	CITATIONS
440	Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2. <i>GMS Hygiene and Infection Control</i> , 2021, 16, Doc16.	0.2	0
442	Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105153.	1.0	16
443	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. <i>Npj Vaccines</i> , 2021, 6, 143.	2.9	47
445	Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 473-482.	4.6	76
446	The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. <i>ELife</i> , 2021, 10, .	2.8	24
447	COVID-19 vaccinations: The unknowns, challenges, and hopes. <i>Journal of Medical Virology</i> , 2022, 94, 1336-1349.	2.5	75
448	Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. <i>Frontiers in Immunology</i> , 2021, 12, 772240.	2.2	33
449	Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines—A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. <i>Viruses</i> , 2021, 13, 2290.	1.5	7
450	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe</i> , The, 2022, 3, e52-e61.	3.4	436
451	Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. <i>ELife</i> , 2021, 10, .	2.8	63
452	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. <i>Nature Communications</i> , 2021, 12, 6871.	5.8	147
454	Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 252-260.	1.5	380
455	Self-reported mask-related worrying reduces relative avoidance bias toward unmasked faces in individuals with low Covid19 anxiety syndrome. <i>Cognitive Research: Principles and Implications</i> , 2021, 6, 75.	1.1	7
456	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
457	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
459	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
460	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e21-e31.	3.4	131
461	Growth, reproduction numbers and factors affecting the spread of SARS-CoV-2 novel variants of concern in the UK from October 2020 to July 2021: a modelling analysis. <i>BMJ Open</i> , 2021, 11, e056636.	0.8	16

#	ARTICLE	IF	CITATIONS
462	The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. <i>Frontiers in Public Health</i> , 2021, 9, 775224.	1.3	156
464	SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12243.	1.8	8
465	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
466	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
467	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 329-340.	4.6	103
468	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. <i>Cells</i> , 2021, 10, 3367.	1.8	42
469	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	1.2	39
470	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- $\alpha$ inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
473	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
474	Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure. <i>Scientific Reports</i> , 2021, 11, 22630.	1.6	16
475	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study. <i>PLoS ONE</i> , 2021, 16, e0258704.	1.1	12
476	Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 2173-2184.	6.3	261
477	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12.	5.1	52
478	A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. <i>EClinicalMedicine</i> , 2021, 42, 101218.	3.2	21
479	Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115597.	0.8	16
480	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
481	Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones. <i>Frontiers in Endocrinology</i> , 2021, 12, 726696.	1.5	16
482	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. <i>EClinicalMedicine</i> , 2021, 42, 101190.	3.2	22

#	ARTICLE	IF	CITATIONS
483	SARS-CoV-2 Variants: Past, Present and Future. <i>Economics, Law, and Institutions in Asia Pacific</i> , 2022, , 3-23.	0.4	0
484	The political theatre of the UK's travel ban on South Africa. <i>Lancet, The</i> , 2021, 398, 2211-2213.	6.3	37
485	Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. <i>Vaccine</i> , 2022, 40, 524-530.	1.7	50
486	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
487	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4714-4740.	1.4	16
488	Current and future nanoparticle vaccines for COVID-19. <i>EBioMedicine</i> , 2021, 74, 103699.	2.7	57
489	COVID-19 variants that escape vaccine immunity: Global and Indian contextâ€”are more vaccines needed?. <i>Journal of Biosciences</i> , 2021, 46, 1.	0.5	2
490	Motivation of COVID-19 Vaccination Among Hospital Employees: A National Survey. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
491	Temporal Changes in Factors Associated With COVID-19 Vaccine Hesitancy and Uptake Among Adults in Hong Kong. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
492	Overview of genomic surveillance related to Severe Acute Respiratory Syndrom Coronavirus 2 (SARS-) Tj ETQq1 1 0,784314 rgBT /Overl 0,2	0.2	9
493	Not All Covid-19 Waves are Similar: Origins, Detection and Mitigation Strategies for Simultaneous Waves. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
494	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
495	Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B.1.1.7 in Egypt. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105191.	1.0	3
496	Investigating Constraints Along the Plant Secretory Pathway to Improve Production of a SARS-CoV-2 Spike Vaccine Candidate. <i>Frontiers in Plant Science</i> , 2021, 12, 798822.	1.7	6
497	Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. <i>Frontiers in Immunology</i> , 2021, 12, 788235.	2.2	11
498	Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies: a systematic review. <i>Open Research Europe</i> , 0, 2, 4.	2.0	0
499	Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. <i>Current Opinion in Virology</i> , 2022, 52, 89-101.	2.6	2
500	Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers. <i>Journal of Infection and Public Health</i> , 2022, 15, 182-186.	1.9	22

#	ARTICLE	IF	CITATIONS
501	Use of Sanger protocols to identify variants of concern, key mutations and track evolution of SARS-CoV-2. <i>Journal of Virological Methods</i> , 2022, 300, 114422.	1.0	2
502	Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100154.	1.5	55
503	Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. <i>Journal of Infection and Public Health</i> , 2022, 15, 156-163.	1.9	10
504	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	1.0	8
505	Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland. <i>Epidemics</i> , 2022, 38, 100535.	1.5	29
506	A Simple Model to Estimate the Transmissibility of SARS-COV-2 Beta, Delta and Omicron Variants in South Africa. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
507	Basic Research Reveals the Unique Virologic Features of SARS-CoV-2. <i>Trends in the Sciences</i> , 2021, 26, 9_79-9_86.	0.0	0
509	COVID-19 outbreak in a long-term care facility in Kelowna, British Columbia after rollout of COVID-19 vaccine in March 2021. <i>Canada Communicable Disease Report</i> , 2021, 47, 543-552.	0.6	2
510	Forecasting the Severity of COVID-19 Pandemic Amidst the Emerging SARS-CoV-2 Variants: Adoption of ARIMA Model. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-17.	0.7	7
511	Neurological toll of COVID-19. <i>Neurological Sciences</i> , 2022, 43, 2171-2186.	0.9	16
512	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Lancet Infectious Diseases</i> , The, 2022, 22, 636-648.	4.6	52
513	Looking at COVID-19 from a Systems Biology Perspective. <i>Biomolecules</i> , 2022, 12, 188.	1.8	1
515	Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 212-226.	3.0	6
516	Innovative vaccine approachesâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	1.8	5
517	A Case of Acute Viral Pericarditis Complicated With Pericardial Effusion Induced by Third Dose of COVID Vaccination. <i>Cureus</i> , 2022, 14, e21207.	0.2	2
518	SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. <i>Cell Reports Medicine</i> , 2022, 3, 100510.	3.3	51
520	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. <i>Nature Medicine</i> , 2022, 28, 477-480.	15.2	342
521	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9



#	ARTICLE	IF	CITATIONS
522	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <i>Cell</i> , 2022, 185, 872-880.e3.	13.5	165
523	Uptake of the COVID-19 vaccine among healthcare workers in Malawi. <i>International Health</i> , 2023, 15, 77-84.	0.8	21
524	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
525	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. <i>BMC Medicine</i> , 2022, 20, 29.	2.3	20
526	Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. <i>Vaccines</i> , 2022, 10, 82.	2.1	16
527	Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy. <i>View</i> , 2022, 3, .	2.7	7
528	Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. <i>Cureus</i> , 2022, 14, e21721.	0.2	4
529	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. <i>JAMA Network Open</i> , 2022, 5, e2147375.	2.8	30
530	SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron. <i>Frontiers in Immunology</i> , 2022, 13, 801431.	2.2	31
531	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	2.1	13
532	Evaluating Correlates of Protection for Mix-Match Vaccine Against COVID-19 VOCs With Potential of Evading Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
533	The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. <i>Clinical and Molecular Allergy</i> , 2022, 20, 1.	0.8	15
534	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
535	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
536	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
538	Is the BCG Vaccine an Answer to Future Pandemic Preparedness?. <i>Vaccines</i> , 2022, 10, 201.	2.1	0
539	The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 78.	1.5	64
540	Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic. <i>Expert Review of Vaccines</i> , 2022, 21, 427-430.	2.0	30

#	ARTICLE	IF	CITATIONS
541	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	5.1	153
542	Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12179.	5.5	24
543	Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2. <i>Journal of General Virology</i> , 2022, 103, .	1.3	2
545	New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2210755.	0.7	85
547	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. <i>Npj Vaccines</i> , 2022, 7, 7.	2.9	35
548	Assessing the potential impact of immunity waning on the dynamics of COVID-19 in South Africa: an endemic model of COVID-19. <i>Nonlinear Dynamics</i> , 2022, 109, 203-223.	2.7	15
549	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. <i>EBioMedicine</i> , 2022, 75, 103761.	2.7	104
550	Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2022, 5, e2143955.	2.8	99
551	Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2022, 226, 485-496.	1.9	8
552	Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. <i>Journal of Medical Virology</i> , 2022, 94, 2369-2375.	2.5	24
553	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
554	Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. <i>PLoS ONE</i> , 2022, 17, e0260733.	1.1	60
555	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
556	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
557	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). <i>Scientific Reports</i> , 2022, 12, 1727.	1.6	11
558	CoVax501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity. <i>Cell Discovery</i> , 2022, 8, 9.	3.1	12
559	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
560	Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2. <i>Molecular Therapy</i> , 2022, 30, 1926-1940.	3.7	16



#	ARTICLE	IF	CITATIONS
561	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. <i>Virus Research</i> , 2022, 310, 198674.	1.1	24
562	Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains. <i>Nano Today</i> , 2022, 43, 101393.	6.2	2
563	The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1009914.	2.1	26
564	Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library. <i>Antibodies</i> , 2022, 11, 13.	1.2	6
565	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
566	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
567	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
568	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. <i>Nature Microbiology</i> , 2022, 7, 379-385.	5.9	194
569	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
570	Peculiarities of the T Cell Immune Response in COVID-19. <i>Vaccines</i> , 2022, 10, 242.	2.1	24
571	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVID-19 trial. <i>Nature Medicine</i> , 2022, 28, 823-830.	15.2	26
572	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	20
573	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
574	Emerging Vaccine-Breakthrough SARS-CoV-2 Variants. <i>ACS Infectious Diseases</i> , 2022, 8, 546-556.	1.8	59
575	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
576	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 766821.	2.2	15
577	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. <i>Nature Reviews Cardiology</i> , 2022, 19, 314-331.	6.1	46
579	The variants of SARS-CoV-2 and the challenges of vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1366-1372.	2.5	29

#	ARTICLE	IF	CITATIONS
580	COVID-19: comprehensive review on mutations and current vaccines. Archives of Microbiology, 2022, 204, 8.	1.0	26
581	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. Infection, 2022, 50, 309-325.	2.3	112
582	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 0, , .	13.7	72
583	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. Npj Vaccines, 2021, 6, 146.	2.9	14
584	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nature Reviews Immunology, 2022, 22, 57-65.	10.6	217
585	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 2022, 602, 676-681.	13.7	1,038
586	The race for a COVID-19 vaccine: where are we up to?. Expert Review of Vaccines, 2022, 21, 355-376.	2.0	11
591	Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Science Advances, 2021, 7, eabk0172.	4.7	32
592	Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. MBio, 2021, 12, e0265621.	1.8	14
593	Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2). PLoS ONE, 2021, 16, e0260958.	1.1	31
594	Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. EMBO Reports, 2022, 23, e53865.	2.0	18
596	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses, 2021, 13, 2485.	1.5	23
597	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Science Translational Medicine, 2021, , eabm3302.	5.8	13
598	COVID-19 variants that escape vaccine immunity: Global and Indian context-are more vaccines needed?. Journal of Biosciences, 2021, 46, .	0.5	0
599	Adopting an heterologous prime-boost strategy in COVID-19 vaccination, the need for locally generated evidence in Africa. Pan African Medical Journal, 2022, 41, 148.	0.3	1
600	Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects?. SSRN Electronic Journal, 0, , .	0.4	10
601	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. Theranostics, 2022, 12, 2519-2534.	4.6	3
602	Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
603	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 835830.	2.2	19
604	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
605	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. <i>Cell Discovery</i> , 2022, 8, 17.	3.1	23
606	Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. <i>Frontiers in Immunology</i> , 2022, 13, 828053.	2.2	11
607	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
608	Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 350.	2.1	44
609	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
612	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
613	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizerâ€™BioNTech) in Patients on Hemodialysis. <i>Vaccines</i> , 2022, 10, 327.	2.1	7
614	Study of Different Deep Learning Methods for Coronavirus (COVID-19) Pandemic: Taxonomy, Survey and Insights. <i>Sensors</i> , 2022, 22, 1890.	2.1	14
615	A COVID-19 vaccination model for Aotearoa New Zealand. <i>Scientific Reports</i> , 2022, 12, 2720.	1.6	25
616	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. <i>Frontiers in Immunology</i> , 2022, 13, 840707.	2.2	11
617	Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. <i>Cell Discovery</i> , 2022, 8, 16.	3.1	18
618	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. <i>Immunologic Research</i> , 2022, 70, 289-315.	1.3	34
619	Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic. <i>Medical Review</i> , 2022, 2, 66-88.	0.3	12
620	Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. <i>Communications Biology</i> , 2022, 5, 169.	2.0	118
621	Whole genome sequence analysis showing unique SARS-CoV-2 lineages of B.1.524 and AU.2 in Malaysia. <i>PLoS ONE</i> , 2022, 17, e0263678.	1.1	8
622	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	2.1	5

#	ARTICLE	IF	CITATIONS
623	Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	1
624	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. <i>Microbiology Spectrum</i> , 2022, 10, e0169521.	1.2	8
625	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
626	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
627	A Correlation Study of COVID-19 in Europe Considering Different Vaccines, Age Groups and Variants Including Delta and Omicron. <i>BioMed</i> , 2022, 2, 133-169.	0.6	1
629	Sisonke: reaching several goals together. <i>Lancet, The</i> , 2022, 399, 1095-1097.	6.3	1
630	The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 506.	2.1	4
631	VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 435.	2.1	8
632	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
633	Beyond vaccination: messaging from religious leaders can help increase adherence to COVID-19 mitigation guidelines following vaccination. A research note. <i>Social Science Journal</i> , 0, , 1-10.	0.9	8
634	A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. <i>Dermatologic Therapy</i> , 2022, 35, e15461.	0.8	31
635	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. <i>Science</i> , 2022, 375, 1041-1047.	6.0	59
637	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
638	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
639	Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021. <i>Scientific Reports</i> , 2022, 12, 4704.	1.6	9
640	WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations. <i>Vaccine</i> , 2022, 40, 2140-2149.	1.7	11
641	AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 128.	2.3	17
642	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39

#	ARTICLE	IF	CITATIONS
643	Knowledge and Attitudes of Medical Students toward COVID-19 Vaccine in Saudi Arabia. <i>Vaccines</i> , 2022, 10, 541.	2.1	8
644	SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments. <i>Therapeutic Delivery</i> , 2022, 13, 187-203.	1.2	8
645	Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers. <i>Vaccines</i> , 2022, 10, 465.	2.1	5
646	Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	1.4	27
647	Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida. <i>Clinical Infectious Diseases</i> , 2022, 75, 1618-1627.	2.9	4
648	Decoupling of omicron variant infections and severe COVID-19. <i>Lancet, The</i> , 2022, 399, 1047-1048.	6.3	22
649	COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3111.	1.2	1
650	ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago. <i>Vaccines</i> , 2022, 10, 466.	2.1	6
651	Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives. <i>Journal of Drug Targeting</i> , 2022, , 1-11.	2.1	5
652	Vaccines Against COVID-19: A Review. <i>Vaccines</i> , 2022, 10, 414.	2.1	8
653	Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 828402.	1.2	5
654	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 69.	7.1	19
655	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. <i>Pathogens</i> , 2022, 11, 368.	1.2	23
656	A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	49
657	Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a double-edged sword. <i>Journal of Medical Virology</i> , 2022, , .	2.5	8
658	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, 3884.	1.6	11
659	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
660	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	2.0	4

#	ARTICLE	IF	CITATIONS
661	Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile. <i>Clinical Infectious Diseases</i> , 2022, 75, e594-e602.	2.9	27
662	Adaptive and optimized COVID-19 vaccination strategies across geographical regions and age groups. <i>PLoS Computational Biology</i> , 2022, 18, e1009974.	1.5	14
664	Identifying vaccine escape sites via statistical comparisons of short-term molecular dynamics. <i>Biophysical Reports</i> , 2022, 2, 100056.	0.7	2
665	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9
667	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
668	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
669	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. <i>Nature Communications</i> , 2022, 13, 1976.	5.8	27
670	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
671	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. <i>EBioMedicine</i> , 2022, 78, 103962.	2.7	8
672	Multi-scale modelling reveals that early super-spreader events are a likely contributor to novel variant predominance. <i>Journal of the Royal Society Interface</i> , 2022, 19, 20210811.	1.5	16
673	Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 1314-1326.	13.9	303
674	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro. <i>Chinese Medicine</i> , 2022, 17, 40.	1.6	8
676	The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125.	3.6	41
677	Interfering effects on the bioactivities of several key proteins of COVID-19/variants in diabetes by compounds from Lianqiao leaves: In silico and in vitro analyses. <i>International Journal of Biological Macromolecules</i> , 2022, 207, 715-729.	3.6	10
678	Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 23, 100441.	1.3	100
679	Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period. <i>International Immunopharmacology</i> , 2022, 108, 108766.	1.7	12
682	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. <i>Medical Journal of Indonesia</i> , 2022, 30, 264-78.	0.2	1
686	Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. <i>Transactions of the Royal Society of South Africa</i> , 0, , 1-4.	0.8	2



#	ARTICLE	IF	CITATIONS
687	Simulation study reveals factors that affect the predominance of SARS-CoV-2 novel variant. <i>Virology Journal</i> , 2021, 18, 253.	1.4	2
689	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
691	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020â€”March 2021) Using a Statistical Learning Strategy. <i>Viruses</i> , 2022, 14, 9.	1.5	10
692	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	1.5	9
693	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. <i>PLoS Biology</i> , 2021, 19, e3001384.	2.6	15
696	Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 795741.	2.2	13
697	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 75, e857-e864.	2.9	30
698	Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5135-5138.	1.4	11
701	Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, 34.	0.3	5
702	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 857440.	2.2	15
703	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
704	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
705	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
706	Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems. <i>Pharmaceutics</i> , 2022, 14, 856.	2.0	4
707	Development of antibody resistance in emerging mutant strains of SARS CoVâ€2: Impediment for COVIDâ€19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
708	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
709	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
710	Annotating Spike Protein Polymorphic Amino Acids of Variants of SARS-CoV-2, Including Omicron. <i>Biochemistry Research International</i> , 2022, 2022, 1-7.	1.5	3

#	ARTICLE	IF	CITATIONS
712	Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data. <i>Vaccine</i> , 2022, 40, 3203-3209.	1.7	13
713	Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. <i>Journal of Infectious Diseases</i> , 2022, 226, 1551-1555.	1.9	4
714	New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019. <i>Journal of Thoracic Oncology</i> , 2022, 17, 588-591.	0.5	1
715	Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2. <i>Nature Communications</i> , 2022, 13, 2237.	5.8	27
716	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
718	SARS-CoV-2: Evolution and Emergence of New Viral Variants. <i>Viruses</i> , 2022, 14, 653.	1.5	39
720	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
721	COVID-19 epidemic in remote areas of the French Amazon, March 2020 to May 2021: Another reality. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2022, 55, e02742021.	0.4	1
722	Rapid Genotyping of Sars-Cov-2 Variants with a Duplex-Targeting Lateral Flow Strip by Crispr-Cas 12a/13a in Pam Independent Manner. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
723	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
724	SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2042-2056.	1.9	8
725	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
726	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
727	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. <i>Viruses</i> , 2022, 14, 854.	1.5	5
728	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	2.2	12
729	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. <i>Pathogens</i> , 2022, 11, 516.	1.2	10
730	Would New SARS-CoV-2 Variants Change the War against COVID-19?. <i>Epidemiologia</i> , 2022, 3, 229-237.	1.1	3
731	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 702.	2.1	18



#	ARTICLE	IF	CITATIONS
732	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. <i>Future Virology</i> , 2022, 17, 403-413.	0.9	6
733	Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. <i>MBio</i> , 2022, 13, e0018122.	1.8	20
734	Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. <i>Biomedicines</i> , 2022, 10, 996.	1.4	3
735	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
736	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	2.2	25
737	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
738	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19). <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 38.	2.7	11
739	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
740	Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. <i>Nature Medicine</i> , 2022, 28, 1476-1485.	15.2	24
741	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
743	Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review. <i>Immunological Medicine</i> , 2022, 45, 225-237.	1.4	18
744	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
746	Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. <i>Lancet HIV</i> , 2022, 9, e309-e322.	2.1	38
747	Robust models of disease heterogeneity and control, with application to the SARS-CoV-2 epidemic. <i>PLOS Global Public Health</i> , 2022, 2, e0000412.	0.5	0
748	Lessons from past pandemics: a systematic review of evidence-based, cost-effective interventions to suppress COVID-19. <i>Systematic Reviews</i> , 2022, 11, 90.	2.5	17
749	Covishield vaccine induces robust immune responses in Bangladeshi adults. <i>IJID Regions</i> , 2022, 3, 211-217.	0.5	5
750	Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2022, 22, 100463.	1.3	8
752	COVID-19 Vaccination and Public Health Countermeasures on Variants of Concern in Canada: Evidence From a Spatial Hierarchical Cluster Analysis. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e31968.	1.2	5

#	ARTICLE	IF	CITATIONS
753	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
754	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
755	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. <i>EBioMedicine</i> , 2022, 80, 104062.	2.7	10
756	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
757	Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91.	0.4	22
758	SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. <i>ELife</i> , 2022, 11, .	2.8	34
759	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3
760	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. <i>Science Bulletin</i> , 2022, 67, 1372-1387.	4.3	54
761	A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 4091-4114.	1.7	6
762	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
763	Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia. <i>Vaccines</i> , 2022, 10, 851.	2.1	15
764	Leveraging South African <sc>HIV</sc> research to define <sc>SARSâ€CoV</sc>â€2 immunity triggered by sequential variants of concern. <i>Immunological Reviews</i> , 2022, 310, 61-75.	2.8	6
765	Prognosis of patients with acute respiratory failure due to the SARS-CoV-2 501Y.V2 variant: a multicenter retrospective matched cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
766	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
767	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
768	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
769	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. <i>Cell Reports</i> , 2022, 39, 110924.	2.9	20
770	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149

#	ARTICLE	IF	CITATIONS
771	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
773	Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteinsâ€”A Possible Signature of Adaptive Selection. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7
774	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
775	ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. <i>Vaccines</i> , 2022, 10, 959.	2.1	3
778	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
779	Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
780	SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339.	1.4	24
781	Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3107-3122.	2.5	5
782	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
783	Advancements in Testing Strategies for COVID-19. <i>Biosensors</i> , 2022, 12, 410.	2.3	8
784	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections. <i>Clinical Infectious Diseases</i> , 2022, 75, S136-S140.	2.9	3
785	Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S110-S120.	2.9	10
786	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 905.	2.1	5
787	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2022, 7, 974-985.	5.9	30
788	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
789	Rapid and accurate identification of SARS-CoV-2 Omicron variants using droplet digital PCR (RT-ddPCR). <i>Journal of Clinical Virology</i> , 2022, 154, 105218.	1.6	12
790	Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	9
791	Fiction and Facts about BCG Imparting Trained Immunity against COVID-19. <i>Vaccines</i> , 2022, 10, 1006.	2.1	10

#	ARTICLE	IF	CITATIONS
792	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
793	How has COVID-19 affected dentistry practice? The perspective of future changes in a comprehensive literature review. <i>SRM Journal of Research in Dental Sciences</i> , 2022, 13, 58.	0.1	0
794	Booster vaccination against SARS-CoV-2: current challenges and solutions. <i>Complex Issues of Cardiovascular Diseases</i> , 2022, 11, 196-203.	0.3	3
795	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. <i>Emerging Microbes and Infections</i> , 2022, 11, 1890-1899.	3.0	12
797	An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 224, 107029.	2.6	5
798	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	23
799	COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2022, 21, .	1.7	6
800	A paper-based assay for the colorimetric detection of SARS-CoV-2 variants at single-nucleotide resolution. <i>Nature Biomedical Engineering</i> , 2022, 6, 957-967.	11.6	83
801	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <i>Current Pharmaceutical Design</i> , 2022, 28, 2901-2913.	0.9	3
802	Advances in COVID-19 Vaccines and New Coronavirus Variants. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
803	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	1.9	16
804	The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans. <i>Therapie</i> , 2023, 78, 293-302.	0.6	1
805	Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1873-1881.	2.0	4
806	EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 – AN OVERVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 6-16.	0.3	1
807	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. <i>Vaccines</i> , 2022, 10, 1071.	2.1	14
809	A Visual Assay of a Loop-Mediated Isothermal Amplification Based Vertical Immunoassay for SARS-CoV-2 RNA Detection. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
810	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
811	Clinical Performance Characteristics of the Swift Normalase Amplicon Panel for Sensitive Recovery of Severe Acute Respiratory Syndrome Coronavirus 2 Genomes. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 963-976.	1.2	7

#	ARTICLE	IF	CITATIONS
812	Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1301-1318.	2.0	12
813	A comprehensive genomic study, mutation screening, phylogenetic and statistical analysis of SARS-CoV-2 and its variant omicron among different countries. <i>Journal of Infection and Public Health</i> , 2022, 15, 878-891.	1.9	24
814	Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 12, 100296.	1.5	5
815	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. <i>EClinicalMedicine</i> , 2022, 50, 101529.	3.2	3
816	A comparison of high-throughput SARS-CoV-2 sequencing methods from nasopharyngeal samples. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
817	Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo. <i>Advanced Science</i> , 2022, 9, .	5.6	9
818	A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
819	Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants. <i>CheM</i> , 2022, 8, 2766-2783.	5.8	18
820	Classifying COVID-19 Variants Based on Genetic Sequences Using Deep Learning Models. <i>Springer Series in Reliability Engineering</i> , 2023, , 347-360.	0.3	3
821	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8177.	1.8	5
822	SARS-CoV-2's Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
823	Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. <i>EClinicalMedicine</i> , 2022, 51, 101569.	3.2	58
824	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
826	Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	8
827	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. <i>Journal of Diabetes and Metabolic Disorders</i> , 2022, 21, 1763-1783.	0.8	4
828	Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.	1.5	27
829	Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 311-323.	1.1	7
830	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0

#	ARTICLE	IF	CITATIONS
832	The SARS-CoV-2 Variants and their Impacts. <i>Journal of Pure and Applied Microbiology</i> , 2022, 16, 1409-1424.	0.3	3
833	Adverse Events following Immunization with COVID-19 Vaccines: A Narrative Review. <i>BioMed Research International</i> , 2022, 2022, 1-11.	0.9	12
834	A universal <sc>SARSâ€CoV DNA</sc> vaccine inducing highly crossâ€reactive neutralizing antibodies and T cells. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	11
835	Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	9
836	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
837	Evolutionary remodelling of Nâ€terminal domain loops fineâ€tunes <sc>SARSâ€CoV</sc>â€2 spike. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
838	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
839	RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. <i>MSphere</i> , 2022, 7, .	1.3	8
840	Nanoparticles in clinical trials of COVID-19: An update. <i>International Journal of Surgery</i> , 2022, 104, 106818.	1.1	22
841	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2211-2233.	0.9	1
842	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
843	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
844	Efficacy and safety of COVIDâ€19 vaccines: A network metaâ€analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	0.7	14
845	The current status of COVID-19 vaccines. A scoping review. <i>Drug Discovery Today</i> , 2022, 27, 103336.	3.2	7
846	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. <i>Journal of Clinical Immunology</i> , 2023, 43, 31-45.	2.0	4
847	Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. <i>Vaccines</i> , 2022, 10, 1251.	2.1	10
848	Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
849	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5



#	ARTICLE	IF	CITATIONS
850	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
851	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
852	Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.. <i>Immunology Letters</i> , 2022, 250, 1-6.	1.1	3
853	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
854	Global Impact of Coronavirus Disease 2019 (COVID-19). <i>Health</i> , 2022, 14, 788-809.	0.1	1
855	A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 10361-10373.	1.0	5
856	Emergence of COVID-19 Variants and Its Global Impact. , 2022, , 183-201.		1
857	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
858	Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
859	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
860	Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
861	Different Platforms, Immune Response Modulators and Challenges in SARS-CoV-2 Vaccination. , 2022, , 539-559.		0
862	Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-PLUS: Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
863	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	14
864	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
865	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
866	COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021â€“2022. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	7
867	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 2383-2392.	3.0	44

#	ARTICLE	IF	CITATIONS
869	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
870	Coronavirus Disease 2019 (COVID-19) Pandemic across Africa: Current Status of Vaccinations and Implications for the Future. <i>Vaccines</i> , 2022, 10, 1553.	2.1	28
871	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
872	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
873	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	0.4	4
874	Molecular modelling on multiepitope-based vaccine against SARS-CoV-2 using immunoinformatics, molecular docking, and molecular dynamics simulation. <i>SAR and QSAR in Environmental Research</i> , 2022, 33, 649-675.	1.0	3
875	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
876	Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	6
877	SARS-CoV-2 variants from COVID-19 positive cases in the Free State province, South Africa from July 2020 to December 2021. <i>Frontiers in Virology</i> , 0, 2, .	0.7	2
878	Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. <i>Communications Biology</i> , 2022, 5, .	2.0	13
879	Recent advances in small-molecular therapeutics for COVID-19. <i>Precision Clinical Medicine</i> , 2022, 5, .	1.3	9
880	One vaccine to counter many diseases? Modeling the economics of oral polio vaccine against child mortality and COVID-19. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
881	Development of variantâ€proof severe acute respiratory syndrome coronavirus 2, panâ€sarbecovirus, and panâ€coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
882	COVIDâ€™19: Clinical status of vaccine development to date. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 114-149.	1.1	8
883	Detecting and mitigating simultaneous waves of COVID-19 infections. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
885	Efficacy of Bacillus Calmetteâ€GuÃ©rin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial. <i>Infectious Diseases and Therapy</i> , 2022, 11, 2205-2217.	1.8	22
886	Probabilistic Approach to COVID-19 Data Analysis and Forecasting Future Outbreaks Using a Multi-Layer Perceptron Neural Network. <i>Diagnostics</i> , 2022, 12, 2539.	1.3	9
887	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10



#	ARTICLE	IF	CITATIONS
888	Broad Antiviral Effects of Echinacea purpurea against SARS-CoV-2 Variants of Concern and Potential Mechanism of Action. <i>Microorganisms</i> , 2022, 10, 2145.	1.6	3
889	SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 1541-1573.	1.4	4
891	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1bâ€“2a trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 295-306.	4.6	14
892	SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
893	SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. <i>Nature Communications</i> , 2022, 13, .	5.8	14
894	Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. <i>Cell Host and Microbe</i> , 2022, 30, 1732-1744.e7.	5.1	7
895	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
896	Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants. <i>Vaccine</i> , 2022, 40, 6706-6710.	1.7	2
897	Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity. <i>Vaccine</i> , 2022, 40, 6864-6872.	1.7	1
899	Effektive Wirkstoffforschung zur PandemieprÃvention. , 2022, , 78-82.		0
900	A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
901	Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
902	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. <i>Expert Review of Vaccines</i> , 2022, 21, 1739-1761.	2.0	2
903	Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13478.	1.8	3
904	IgA quantification as a good predictor of the neutralizing antibodies levels after vaccination against SARS-CoV-2. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100121.	0.4	4
905	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5
906	Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets. <i>Npj Vaccines</i> , 2022, 7, .	2.9	0
907	Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. <i>EBioMedicine</i> , 2022, 86, 104341.	2.7	20

#	ARTICLE	IF	CITATIONS
908	SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies. <i>Seminars in Hematology</i> , 2022, 59, 192-197.	1.8	5
909	A systematic review of strategies adopted to scale up COVID-19 testing in low-, middle- and high-income countries. <i>BMJ Open</i> , 2022, 12, e060838.	0.8	5
910	SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity. <i>Virus Evolution</i> , 2022, 8, .	2.2	4
911	COVID-19 vaccines: Update of the vaccines in use and under development. <i>Vacunas (English Edition)</i> , 2022, 23, S88-S102.	0.3	0
912	T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa. <i>Aids</i> , 2023, 37, 105-112.	1.0	4
913	Spatiotemporal impact of non-pharmaceutical interventions against COVID-19 on the incidence of infectious diarrhea in Xi'an, China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
914	COVID-19 Vaccination Acceptance and its Predicting Factors Among Internet Users in Ho Chi Minh City and Other Regions in Vietnam. <i>The Open Covid Journal</i> , 2022, 2, .	0.4	0
915	Modelling optimal lockdowns with waning immunity. <i>Economic Theory</i> , 2024, 77, 197-234.	0.5	7
917	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
918	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
919	Efficacy and Safety of COVID-19 Vaccines—An Update. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 112.	1.0	11
920	Perspectives on the COVID-19 vaccine uptake: a qualitative study of community members and health workers in Zambia. <i>BMJ Open</i> , 2022, 12, e058028.	0.8	4
921	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
922	Amino acid variants of SARS-CoV-2 papain-like protease have impact on drug binding. <i>PLoS Computational Biology</i> , 2022, 18, e1010667.	1.5	3
925	Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawaii—mi to facilitate public-health policies. <i>PLoS ONE</i> , 2022, 17, e0278287.	1.1	0
926	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
927	Evaluating the value of anti-SARS-CoV-2 antibody detection and neutralizing responses with euvirus: a population of 10776 close contacts in the epidemic of Fujian. <i>Clinica Chimica Acta</i> , 2022, , .	0.5	0
928	Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. <i>Nature Communications</i> , 2022, 13, .	5.8	18

#	ARTICLE	IF	CITATIONS
929	SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. <i>Vaccines</i> , 2022, 10, 2145.	2.1	4
930	Vaccinated Healthcare Workers's Adherence to COVID-19 Prevention Measures and Associated Factors in Northwest Ethiopia: A Facility-Based Cross-Sectional Study. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 2389-2398.	1.2	0
931	Policy and Guideline Review of Vaccine Safety for COVID-19 in Pregnant Women in Southern Africa, with a Particular Focus on South Africa. <i>Vaccines</i> , 2022, 10, 2077.	2.1	0
933	ViralVar: A Web Tool for Multilevel Visualization of SARS-CoV-2 Genomes. <i>Viruses</i> , 2022, 14, 2714.	1.5	3
934	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
935	Retrospective in silico mutation profiling of SARS-CoV-2 structural proteins circulating in Uganda by July 2021: Towards refinement of COVID-19 disease vaccines, diagnostics, and therapeutics. <i>PLoS ONE</i> , 2022, 17, e0279428.	1.1	0
936	Immediate and 6-month seizure outcomes following first and second SARS-CoV2 mRNA vaccinations: A multicenter study with a nationwide survey. <i>Epilepsy and Behavior</i> , 2023, 139, 109070.	0.9	1
937	Structural Analysis and Epitope Prediction of S2 Domain of SARS-CoV-2, Conservation Analysis Among Major Variants. <i>Viral Immunology</i> , 0, , .	0.6	0
938	Rapid and Flexible RT-qPCR Surveillance Platforms To Detect SARS-CoV-2 Mutations. <i>Microbiology Spectrum</i> , 0, , .	1.2	4
939	Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
940	COVID-19 Vaccines All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
941	Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. <i>The Lancet Regional Health Americas</i> , 2023, 18, 100423.	1.5	16
942	Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development. <i>Life Sciences</i> , 2023, 315, 121374.	2.0	3
944	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. <i>Vaccines</i> , 2023, 11, 51.	2.1	9
945	Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	1
946	Propagation of SARS-CoV-2 in a Closed Cell Culture Device: Potential GMP Compatible Production Platform for Live-Attenuated Vaccine Candidates under BSL-3 Conditions?. <i>Viruses</i> , 2023, 15, 397.	1.5	0
947	Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. <i>Vaccines</i> , 2023, 11, 299.	2.1	5
948	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0

#	ARTICLE	IF	CITATIONS
949	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. <i>JAMA Network Open</i> , 2023, 6, e2253301.	2.8	0
950	Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. <i>Viruses</i> , 2023, 15, 448.	1.5	0
951	An Observational Study on Patients With COVID-19 Infection Admitted to the Intensive Care Unit With Respect to Their Vaccination Status. <i>Cureus</i> , 2023, , .	0.2	0
952	Willingness to receive COVID-19 booster dose and its associated factors in Ghana: A cross-sectional study. <i>Health Science Reports</i> , 2023, 6, .	0.6	3
953	Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	3.4	46
954	Immunological interactions in helminths-SARS CoV-2 coinfection: Could old enemy be a friend today?. <i>Parasite Immunology</i> , 2023, 45, .	0.7	4
955	Sustainable production of dimethyl-protected cyclic lysine over Pd/m-Al <sub>2</sub> O <sub>3</sub> -Si catalysts and its application in synthesis of antibacterial nylon-6 copolymers. <i>Chemical Engineering Journal</i> , 2023, 463, 142504.	6.6	1
956	Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers. <i>Vaccine: X</i> , 2023, 14, 100288.	0.9	1
957	Targeting intracellular Neu1 for coronavirus infection treatment. <i>IScience</i> , 2023, 26, 106037.	1.9	5
958	Antibodies, B Cell Responses and Immune Responses to SARS-CoV-2 Infections. <i>Antibodies</i> , 2023, 12, 12.	1.2	0
960	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3255.	1.8	4
961	The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2023, 38, 840-852.	0.4	8
962	Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
963	Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4398.	1.8	0
964	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
965	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
966	A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 513.	2.1	5
967	Insights into organoid-based modeling of COVID-19 pathology. <i>Virology Journal</i> , 2023, 20, .	1.4	1

#	ARTICLE	IF	CITATIONS
968	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
969	Higher plasma levels of thymosin- $\alpha$ 1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	1
970	Variants of SARS-CoV-2: Influences on the Vaccines <sup>TM</sup> Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
971	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. <i>American Journal of Epidemiology</i> , 0, , .	1.6	1
972	Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4796.	1.2	2
973	Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity. <i>Vaccines</i> , 2023, 11, 655.	2.1	3
974	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
975	Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
976	SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. <i>Vaccines</i> , 2023, 11, 682.	2.1	7
977	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5944.	1.8	12
978	Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac <sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. <i>Vaccines</i> , 2023, 11, 715.	2.1	1
979	The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa. <i>BMC Public Health</i> , 2023, 23, .	1.2	2
980	A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6369.	1.8	4
981	The origins of new SARS-COV-2 variants in immunocompromised individuals. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 148-156.	1.5	3
983	HLA Variation and SARS-CoV-2 Specific Antibody Response. <i>Viruses</i> , 2023, 15, 906.	1.5	4
984	The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy. <i>PeerJ</i> , 0, 11, e15024.	0.9	4
985	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. <i>Viruses</i> , 2023, 15, 944.	1.5	19
986	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. <i>Nature Communications</i> , 2023, 14, .	5.8	12

#	ARTICLE	IF	CITATIONS
987	Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. Zoonoses, 2023, 3, .	0.5	1
1014	Epidemic Patterns of Emerging Variants with Dynamical Social Distancing. , 2023, , 215-232.		0
1016	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
1017	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
1028	The Opportunity of Data-Driven Services for Viral Genomic Surveillance. , 2023, , .		0
1038	Molecular and serological testing in the setting of a global pandemic. , 2024, , 199-216.		0
1042	Harnessing synthetic biology for advancing RNA therapeutics and vaccine design. Npj Systems Biology and Applications, 2023, 9, .	1.4	0